Clinical Trial Update: Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating the combination of everolimus, octreotide LAR, and metformin in well-differentiated pancreatic neuroendocrine tumors; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Well Differentiated Pancreatic Endocrine Tumor

Drugs mentioned

• Everolimus (everolimus)
• Octreotide LAR (octreotide long-acting release)
• metformin (metformin)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Well Differentiated Pancreatic Endocrine Tumor | Phase 2 | Status: UNKNOWN